BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32067942)

  • 1. The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer.
    Seltzer S; Corrigan M; O'Reilly S
    Exp Mol Pathol; 2020 Jun; 114():104404. PubMed ID: 32067942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
    Malmgren JA; Mayer M; Atwood MK; Kaplan HG
    Breast Cancer Res Treat; 2018 Jan; 167(2):579-590. PubMed ID: 29039120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Characterization of
    Garrido-Castro AC; Spurr LF; Hughes ME; Li YY; Cherniack AD; Kumari P; Lloyd MR; Bychkovsky B; Barroso-Sousa R; Di Lascio S; Jain E; Files J; Mohammed-Abreu A; Krevalin M; MacKichan C; Barry WT; Guo H; Xia D; Cerami E; Rollins BJ; MacConaill LE; Lindeman NI; Krop IE; Johnson BE; Wagle N; Winer EP; Dillon DA; Lin NU
    Clin Cancer Res; 2021 Feb; 27(4):1105-1118. PubMed ID: 33293374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
    Lao C; Kuper-Hommel M; Elwood M; Campbell I; Edwards M; Lawrenson R
    Breast Cancer; 2021 Mar; 28(2):387-397. PubMed ID: 33044617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HR
    Torrisi R; Jacobs F; Miggiano C; De Sanctis R; Santoro A
    Drugs Context; 2023; 12():. PubMed ID: 36926051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients.
    McKenzie HS; Maishman T; Simmonds P; Durcan L; ; Eccles D; Copson E
    Br J Cancer; 2020 May; 122(11):1618-1629. PubMed ID: 32231292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990-2011.
    Malmgren J; Hurlbert M; Atwood M; Kaplan HG
    Breast Cancer Res Treat; 2019 Apr; 174(2):505-514. PubMed ID: 30560462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of De Novo Metastatic Breast Cancer.
    Daily K; Douglas E; Romitti PA; Thomas A
    Clin Breast Cancer; 2021 Aug; 21(4):302-308. PubMed ID: 33750642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Characterization of De Novo Metastatic Breast Cancer.
    Mullangi S; Vasan N
    Clin Breast Cancer; 2022 Feb; 22(2):98-102. PubMed ID: 34949553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.
    Müller V; Hein A; Hartkopf AD; Fasching PA; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lüftner D; Wallwiener M; Beckmann MW; Schneeweiss A; Belleville E; Uhrig S; Wimberger P; Hielscher C; Meyer J; Wurmthaler LA; Kurbacher CM; Wuerstlein R; Untch M; Janni W; Taran FA; Lux MP; Wallwiener D; Brucker SY; Fehm TN; Michel LL
    Eur J Cancer; 2022 Sep; 172():13-21. PubMed ID: 35728342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and follow-up of metastatic breast cancer in Ethiopia: A cohort study of 573 women.
    Weiner CM; Mathewos A; Addissie A; Ayele W; Aynalem A; Wondemagegnehu T; Wienke A; Jemal A; Zerche P; Thomssen C; Seidler A; Kantelhardt EJ
    Breast; 2018 Dec; 42():23-30. PubMed ID: 30149234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
    den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
    Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
    Chen J; Wu X; Christos PJ; Formenti S; Nagar H
    Breast Cancer Res; 2018 Apr; 20(1):26. PubMed ID: 29661221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer metastasis to gynaecological organs: a clinico-pathological and molecular profiling study.
    Kutasovic JR; McCart Reed AE; Males R; Sim S; Saunus JM; Dalley A; McEvoy CR; Dedina L; Miller G; Peyton S; Reid L; Lal S; Niland C; Ferguson K; Fellowes AP; Al-Ejeh F; Lakhani SR; Cummings MC; Simpson PT
    J Pathol Clin Res; 2019 Jan; 5(1):25-39. PubMed ID: 30246500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
    Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
    Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse.
    Yang J; Wu NN; Huang DJ; Luo YC; Huang JZ; He HY; Lu HL; Song WL
    Tumour Biol; 2017 Jul; 39(7):1010428317713492. PubMed ID: 28720060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy.
    Zhou J; Qian S; Li H; He W; Tan X; Zhang Q; Han G; Chen G; Luo R
    Tumour Biol; 2015 May; 36(5):3941-7. PubMed ID: 25773385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis.
    Gaillard T; Carton M; Mailliez A; Desmoulins I; Mouret-Reynier MA; Petit T; Leheurteur M; Dieras V; Ferrero JM; Uwer L; Guiu S; Gonçalves A; Levy C; Debled M; Dalenc F; Patsouris A; Bachelot T; Eymard JC; Chevrot M; Conversano A; Robain M; Hequet D
    Eur J Cancer; 2021 Oct; 158():181-188. PubMed ID: 34689042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
    Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
    Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival differences among women with de novo stage IV and relapsed breast cancer.
    Dawood S; Broglio K; Ensor J; Hortobagyi GN; Giordano SH
    Ann Oncol; 2010 Nov; 21(11):2169-2174. PubMed ID: 20427349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.